ARTICLE | Finance
Ebb & Flow
April 18, 2005 7:00 AM UTC
As the sign says, "objects in the rear view mirror are closer than they appear."
On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and positive earnings, Genentech (DNA) added $12.9 billion in market cap and now sits at $76 billion. ...